Please login to the form below

Not currently logged in
Email:
Password:

Nektar Therapeutics appoints Jeff Ajer

He joins as an independent director

California, US-based Nektar Therapeutics has appointed Jeff Ajer as its independent director to the company’s board of directors, following his 25 years’ of biotechnology and industry experience.

Ajer’s expertise includes driving commercial operations within rare diseases and speciality medicines and he joins the group from BioMarin, where he served as an executive vice president and chief commercial officer.

There he worked on establishing BioMarin’s global footprint and commercial infrastructure and has played a leadership role in the launches and growth strategies for brands including Brineura, Vimizim, Kuvan and Naglazyme.

He said: “I am honoured to join Nektar’s board during an exciting time in the company’s evolution and growth.

“Over the course of my career, I have had the great pleasure of shaping the growth strategies for various commercial brands across a variety of disease state, and I look forward to leveraging these experiences for Nektar as a new board member.”

Prior to BioMarin, Ajer served as vice president, global transplant operations at Genzyme Corporation, and has held roles in sales, marketing and operations at SangStat Medical Corporation and ICN Pharmaceuticals.

Howard Robin, president and CEO, Nektar Therapeutics, said: “Jeff’s extensive leadership experience within rapidly growing biotechnology companies is a great addition to our board as we continue to build Nektar’s wholly-owned pipeline of innovative drug candidates.

“This appointment adds to the existing expertise of our highly-respected board members as they guide Nektar toward continued growth and success.”

29th September 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics